CD31 peptides

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10815272
APP PUB NO 20150203536A1
SERIAL NO

14408789

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides peptides corresponding to fragments of CD31 that inhibit platelet and leukocyte activation, and to their use in the treatment of thrombotic disease. These peptides find use as therapeutic agents in the treatment of inflammatory diseases and thrombotic diseases such as atherothrombosis, in particular when immobilised onto solid supports.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITÉ PARIS CITÉ85 BOULEVARD SAINT GERMAIN PARIS 75006

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Caligiuri, Giuseppina Paris, FR 14 9
Nicoletti, Antonino Paris, FR 15 9

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 27, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 27, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00